Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.68 |
| ▸ | SCN2B | O60939 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.56 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036783 | 0.96 | SCN9A (0.73) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL16239622 | 0.86 | SCN9A (0.76) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| Diethylamine SCHEMBL16239552 | 0.84 | SCN9A (0.64) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| Diethylamine SCHEMBL16239701 | 0.81 | SCN9A (0.58) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL16178222 | 0.81 | SCN9A (1.00) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL14892882 | 0.79 | SCN9A (0.69) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL16178020 | 0.79 | SCN9A (0.81) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL15018172 | 0.78 | SCN9A (0.66) | SCN9ASCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL16178139 | 0.78 | SCN9A (0.84) | SCN9A | |
| SCHEMBL15017892 | 0.78 | SCN9A (1.00) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791108-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2016-07-27 | — | — | EP | disclosed |
| US-9085517-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-20140315879-A1 | Sulfonamide Derivatives | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315879-A1 | Sulfonamide Derivatives | SCN7A, SCN1B, SCN1A | SCN9A 13/4885SCN2B 4/4885SCN1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.